Clay Siegall is widely recognized for the inception of Seattle Genetics in 1998. Since then, Clay Siegall has been serving the company in several capacities including the chairperson of the board of directors, chief executive officer as well as president. Under Clay’s management, Seattle Genetics has attained significant milestones in the formation of a vast pipeline of antibody-based cancer therapies including ADCETRIS (brentuximab vedotin).
Siegall is a proud holder of several higher academic level qualifications.They include a zoology degree and a Ph.D. in Genetics from the University of Maryland and the George Washington University respectively. This level of academic knowledge has come in handy in spearheading the operations of Seattle Genetics.
Clay is acknowledged for his instrumental role in spearheading Seattle Genetics’ capital-raising endeavors. Through his assistance, the company secured over $675 million in both public as well as private funding. These capital-raising activities also included Seattle Genetics’ initial public offering, which was done in 2001. Thanks to his exceptional leadership, Seattle Genetics boasts of multiple strategic ADC technology licenses with several companies like Pfizer, GlaxoSmithKline, Genentech and Abbvie.
Clay’s Commitment to Cancer Research
Before co-founding the Bothell-based Seattle Genetics, he worked with other research entities. They include the National Institutes of Health, Bristol-Myers Squibb Pharmaceutical Research Institute, and the National Cancer Institute. Apart from his roles at Seattle Genetics, he serves as a board member of several companies including Ultragenyx Mirna Therapeutics and Alder BioPharmaceuticals.
Seattle Genetics and its Operations
Seattle Genetics is a renowned biotechnology company. Its focus and research for antibody-based therapies have positioned the company as a premier developer of antibody-drug conjugates (ADCs). The technology used by Seattle Genetics harness the targeting potential of monoclonal antibodies to supply cell-killing agents to cancer cells.
ADCETRIS is one of the leading programs of Seattle Genetics. Seattle Genetics’ collaboration with Takeda has boosted the availability of ADCETRIS. Currently, the drug is commercially present in over 50 nations around the globe such as the European Union member countries, United States, Canada and Japan. Other than ADCETRIS, Seattle’s diverse product pipeline also consists of other products including SGN-CD70A, SGN-LIV1A, SGN-CD19A, SGN-CD33A among many others.